- Adjusted Earnings Per Share (EPS): 43.4p, beating the estimate of 38.6p
- Revenue: GBP7.88 billion, surpassing the estimate of GBP7.5 billion
- Vaccine Sales: GBP2.00 billion, below the estimate of GBP2.19 billion
- Shingrix Revenue: GBP832 million, under the estimate of GBP1.01 billion
- Arexvy Revenue: GBP62 million, lagging behind the estimate of GBP77.8 million
- Bexsero Revenue: GBP232 million, exceeding the estimate of GBP200.1 million
- Triumeq Revenue: GBP346 million, above the estimate of GBP334.6 million
- Tivicay Revenue: GBP318 million, almost in line with the estimate of GBP318.2 million
- Dovato Revenue: GBP551 million, higher than the estimate of GBP518 million
- Juluca Revenue: GBP176 million, surpassing the estimate of GBP170.1 million
- Cabenuva Revenue: GBP245 million, slightly below the estimate of GBP257.1 million
- Nucala Revenue: GBP482 million, exceeding the estimate of GBP464.4 million
- Benlysta Revenue: GBP418 million, above the estimate of GBP391.8 million
- Zejula Revenue: GBP165 million, beating the estimate of GBP139 million
- Adjusted Operating Profit: GBP2.51 billion, higher than the estimate of GBP2.21 billion
- Adjusted Operating Margin: 31.9%, surpassing the estimate of 30%
- R&D Expenses: GBP1.42 billion, higher than the estimate of GBP1.38 billion
- General and Administrative Expenses: GBP2.22 billion, slightly above the estimate of GBP2.21 billion
- Core Operating Profit Growth: now expected to grow between 11 to 13 per cent, revised from the previous estimate of 9 to 11 per cent
- Full-Year Guidance: revised at constant exchange rates (CER)
- Royalty Income: expected to be around GBP600 million for the full year
- R&D Expenditure: expected to increase slightly below sales growth
- Core Effective Tax Rate: anticipated to increase to around 17% for the full year due to new global minimum corporate income tax rules
- Analyst Ratings: 13 buys, 12 holds, 3 sells
A look at GlaxoSmithKline PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
GlaxoSmithKline PLC, a research-based pharmaceutical company, has received a mix of Smartkarma Smart Scores indicating its long-term outlook. With a strong dividend score of 4, investors may find the company appealing for potential income generation. The growth score of 3 suggests moderate growth opportunities, while the momentum score of 3 indicates stable market momentum.
However, GlaxoSmithKline PLC scored lower in the value and resilience categories, with scores of 2, reflecting some challenges in terms of valuation and resilience to market fluctuations. Despite this, the company’s diverse product offerings in vaccines, prescription medicines, and consumer health products position it well to cater to various health needs such as infections, depression, and chronic diseases like cancer and heart conditions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
